A CX3CR1 genotype associated with retinal vasculitis in patients in the United Kingdom

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 7, 2006, Pages 2966-2970

  Wallace, Graham R ^a,b   Vaughan, Robert W ^a   Kondeatis, Elly ^a   Mathew, Rashmi ^a   Chen, Yuanneng ^a   Graham, Elizabeth M ^a   Stanford, Miles R ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, HUMAN; PRIMER DNA;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HUMAN; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RETINA VASCULITIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM; CHEMISTRY; GENETIC POLYMORPHISM; GENETICS; POLYMERASE CHAIN REACTION;

DNA PRIMERS; FEMALE; GENOTYPE; GREAT BRITAIN; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, CHEMOKINE; RETINAL VASCULITIS;

EID: 33746754281     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1631     Document Type: Article

References (29)

1. Stanbury RM, Wallace GR, Graham EM. Intermediate uveitis: pars planitis, multiple sclerosis, and retinal vasculitis. Ophthalmol Clin North Am. 1998;11:627-639.
2. Forrester JV. Uveitis: pathogenesis. Lancet. 1991;338:1498-1501.
3. Zlotnick A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
4. Bazan JF, Bacon KB, Hariman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640-644.
5. 3CR1- expressing microglia. Proc Natl Acad Sci. 1998;95:10896-10901.
6. Haskell CA, Cleary MD, Charo IF. Unique role of the chemokine domain of fractalkine in cell capture: kinetics of receptor dissociation with cell adhesion. J Biol Chem. 2000;275:34183-34189.
7. Silverman MD, Zamora DO, Pan Y, et al. Constitutive and inflammatory mediator-regulated fractalkine expression in human ocular tissues and cultured cells. Invest Ophthalmol Vis Sci. 2003;44:1608-1615.
8. 3CR1. Science. 2000;287:2274-2277.
9. 3CR1 polymorphism. J Acquir Immune Defic Syndr. 2001;26:507-511.
10. 3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001;97:1925-1928.
11. 3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 2001;89:401-407.
12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
13. Whitcup SM, Chan CC, Li Q, et al. Expression of cell adhesion molecules in posterior uveitis. Arch Ophthalmol. 1992;110:662-666.
14. Crane IJ, Wallace CA, McKillop-Smith S, Forrester JV. Control of chemokine production at the blood-retinal barrier. Immunology. 2000;101:426-433.
15. Jabs DA, Nussenblatt RB, Rosenbaum JT. The standardization of uveitis nomenclature (SUN) working group: standardization of uveitis nomenclature for reporting clinical data - results of the first international workshop. Am J Ophthalmol. 2005;140:509-516.
16. Malinowski SM, Pulido S, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993;100:818-824.
17. Masterman T, Ligers A, Olsson T, et al. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol. 2000;48:211-219.
18. McDermott DH, Fong AM, Yang Q, et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003;111:1241-1250.
19. 280 variant of the chemokine receptor CX3CR1. J Biol Chem. 2004;279:19649-19657.
20. Lavergne E, Labrueche J, Daoudi M, et al. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:847-853.
21. Cook DN, Chen SC, Sullivan LM, et al. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol. 2001;21:3159-3165.
22. Giessmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19:71-82.
23. Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ. The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol. 2000;165:397-403.
24. Ambati J, Anand A, Fernadez S, et al. An animal model of age-related macular degeneration in senescent CCL2 or CCR2 deficient mice. Nat Med. 2003;9:1390-1397.
25. Tuo J, Smith BC, Bojanowski CM, et al. The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J. 2005;18:1297-1299.
26. Chan CC, Tuo J, Bojanowski CM, Csaky KG, Green WR. Detection of CX3CR1 single nucleotide polymorphism and expression on archived eyes with age-related macular degeneration. Histol Histopathol. 2005;20:857-863.
27. Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1 during acute and chronic inflammation in the rodent CNS. Glia. 2002;37:314-327.
28. Tong N, Perry SW, Zhang Q, et al. Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the CNS. J Immunol. 2000;164:1333-1339.
29. Mizuno T, Kawanokuchi J, Numata K, Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003;25:65-70.